Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial read-outs, shelf registrations, and sudden capital raises make Bicara Therapeutics’ SEC disclosures anything but straightforward. If you have ever searched a 300-page prospectus just to find cash-runway details, you know the challenge.
Our platform solves that problem. Stock Titan’s AI instantly converts dense language into plain-English highlights, letting you understand Bicara Therapeutics SEC documents with AI instead of slogging through technical jargon. Need the latest 8-K material events explained or the most recent Bicara Therapeutics quarterly earnings report 10-Q filing? Every form appears here in real time, tagged and summarized.
Here’s how analysts, portfolio managers, and biotech followers use this page:
- Track Bicara Therapeutics insider trading Form 4 transactions and receive alerts on executive stock transactions Form 4 moments after they hit EDGAR.
- Compare R&D spend, dilution risk, and cash burn with our AI-layered Bicara Therapeutics annual report 10-K simplified notes.
- Dive into pipeline progress via Bicara Therapeutics 8-K material events explained, including interim data disclosures for ficerafusp alfa.
- Review compensation packages through the Bicara Therapeutics proxy statement executive compensation section without hunting across exhibits.
Whether you’re screening biotech investments or verifying a single clinical milestone, our comprehensive coverage—10-K, 10-Q, S-1, 8-K, and Bicara Therapeutics Form 4 insider transactions real-time—keeps you ahead of market-moving details. No more page-count anxiety; the insights you need are surfaced instantly, ready for decisive action.
Vestal Point Capital, LP and Ryan Wilder report ownership of 5,000,000 shares of Bicara Therapeutics Inc. common stock, representing 9.2% of the outstanding shares based on 54,536,218 shares outstanding as of May 8, 2025. The reported interest is held by the Vestal Point fund and a managed account and is shown as shared voting and dispositive power (no sole voting or dispositive power).
The filing identifies Vestal Point as an investment manager and Mr. Wilder as its Chief Investment Officer and managing member. The Reporting Persons state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Bicara Therapeutics is a clinical-stage biopharmaceutical company advancing its lead bifunctional antibody, ficerafusp alfa, into late-stage testing. The company reported $436.6 million in cash and cash equivalents as of June 30, 2025 and an accumulated deficit of $285.3 million. Net losses were $27.4 million for the quarter and $64.2 million for the six months ended June 30, 2025, driven by higher research and development and general and administrative spending as Bicara scales clinical operations and manufacturing.
Bicara initiated the pivotal FORTIFI-HN01 Phase 2/3 program (combination with pembrolizumab) and maintains a collaboration with MSD to supply pembrolizumab for combination cohorts. R&D spending increased materially to support clinical and manufacturing activity, and management expects existing cash to fund operations into the first half of 2029. The company disclosed pending litigation alleging inventorship of patents and reiterated that it will require additional funding over time to advance development and commercialization.
Schedule 13G/A (Am. No. 1) filed for Bicara Therapeutics Inc. (BCAX) shows that investment entities affiliated with Invus have built a passive 9.6 % stake in the company’s common stock as of 30 Jun 2025.
- Invus Public Equities, L.P. directly owns 4,861,944 shares (8.9 %).
- Avicenna Life Sci Master Fund LP holds 355,025 shares (0.7 %).
- Through control of multiple GP/LLC vehicles, Raymond Debbane is deemed to beneficially own a combined 5,216,969 shares, representing the full 9.6 %.
Percentages are based on 54,536,218 shares outstanding reported in the issuer’s 13 May 2025 10-Q. The filing is made under Rule 13d-1(c) and includes the standard certification that the securities were not acquired to change or influence control, indicating a passive investment approach.
The appearance of a sophisticated life-sciences investor just below the 10 % threshold may improve market confidence and liquidity but does not signal activist intent at this stage.
Bicara Therapeutics Inc. (BCAX) – Form 4 insider filing dated 18 Jun 2025 reports transactions by Chief Legal Officer Lara Meisner.
Non-derivative activity: On 16 Jun 2025 Meisner exercised 15,829 options for common stock at an exercise price of $5.45 per share and immediately sold the same 15,829 shares at a weighted-average price of $10.43 (individual sales executed between $10.03-$10.84). As a result, her direct common-stock ownership fell to 0 shares.
Derivative holdings: Two option grants were partially exercised. After the transactions Meisner still directly holds 60,854 options with a $5.45 strike expiring 10 Dec 2033 and 97,443 options with the same strike and expiry, for a total of 158,297 remaining options.
- Grant #1 vests in 16 equal quarterly installments from 14 Dec 2023.
- Grant #2 vested 25 % on 27 Nov 2024; the balance vests in 12 equal quarterly installments thereafter.
Rule 10b5-1 plan: All trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 13 Nov 2024, as disclosed in the Explanation of Responses.
The filing reflects routine option exercise and monetisation by an executive officer, with no change to derivative exposure but the elimination of directly held common shares.
FAQ
What is the current stock price of Bicara Therapeutics (BCAX)?
What is the market cap of Bicara Therapeutics (BCAX)?
